Research programme: respiratory syncytial virus vaccine - GenVec

Drug Profile

Research programme: respiratory syncytial virus vaccine - GenVec

Alternative Names: GV-2311; RSV vaccine - GenVec

Latest Information Update: 17 Nov 2014

Price : $50

At a glance

  • Originator GenVec
  • Developer GenVec; National Institute of Allergy and Infectious Diseases
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Respiratory syncytial virus infections

Most Recent Events

  • 17 Nov 2014 The programme is still available for licensing
  • 11 Nov 2014 Preclinical pharmacodynamics data in Respiratory syncytial virus infections (Prevention) released by GenVec
  • 10 Aug 2012 IND-enabling studies are ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top